Increased research and development efforts have greatly contributed to the growth of the immunoprotein diagnostic testing market in recent years, states a recent report published by Transparency Market Research. The report, titled “Immunoprotein Diagnostic Testing Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019”, indicates that, registering a CAGR of 5.7% from 2013 and 2019, the global immunoprotein diagnostic testing market stands to expand from US$11,019.7 million in 2012 to US$15,351.0 million in 2019.
The research report segments the global immunoprotein diagnostic testing market on the basis of assay technology, immunoprotein type, application, and geography. By the type of immunoprotein tested, the market is categorized into C-reactive protein diagnostic tests, free light chain diagnostic tests, prealbumin diagnostic tests, complement system protein diagnostic tests, immunoglobulin diagnostic tests, and haptoglobin diagnostic tests. The C-reactive protein diagnostic test has been the largest segment owing to its effective and accurate diagnosis of injuries, inflammation-related disorders, strokes, and cardiovascular diseases. However, analysts believe that, being in the initial stages of development, the segment of free light chain diagnostic tests is likely to pick up pace in the near future.
Request Sample Report@ https://www.transparencymarketresearch.com/sample/sample.php?flag=S...
On the basis of technology, the market for immunoprotein diagnostic testing is segmented into enzyme-based immunoassay, radioimmunoassay, chemiluminescence assay, immunofluorescence assay, immunoprotein electrophoresis, and immunoturbidity assay. The chemiluminecence assay segment dominated the global immunoprotein diagnostic testing market in 2012, due to its feasibility for wide-scale application, sensitivity, safety, and ease of use. The segment of radioimmunoassay testing has been losing market share over the years owing to high cost of equipment and devices, strict healthcare regulations, and high exposure to radiation. Doctors and clinicians have switched to safer and more effective tests, leading to a decline in the radioimmunoassay testing market.
Immunoprotein diagnostic testing finds application in endocrine testing, allergy testing, infectious diseases, toxicology testing, oncology testing, and autoimmune disease testing. The report indicates that the segment of oncology testing will generate maximum revenue by the end of the forecast period, presenting a market worth of US$4,943.0 million in 2019 and growing at a CAGR of 6% from 2013 to 2019.The report identifies some of the major factors governing the growth of the immunoprotein diagnostic testing market. According to the report, the growing demand for quick, accurate, and preventive healthcare – especially in emerging economies – is a primary factor boosting the global market. In addition, technological development, commoditization of products, expansion in the field of immunochromatography, and strengthening network of distributors at a global level has also contributed to the growth of the immunoprotein diagnostic testing market. In contrast, high cost of diagnosis is likely to restrict the development of this market over the forecast period.
Some of the leading players in the global immunoprotein diagnostic testing market are DiaSorin SPA, Thermo Fisher Scientific, Inc., The Binding Site Group Ltd., Abcam PLC, Omega Diagnostics Group PLC, Randox Laboratories Ltd., Siemens AG, Enzo Life Sciences, Inc., Roche Holding AG, Fujirebio Diagnostics, Inc., and Abbott Laboratories, Inc. These players are profiled on the basis of parameters such as company and financial overview, recent developments, product portfolio, business strategies, and a SWOT analysis.